| Osteoporosis |
1 |
1 |
| Bone |
0 |
0.63 |
| Bone Density |
0 |
0.59 |
| Estrogen |
0 |
0.51 |
| Hormonal Therapy |
0 |
0.99 |
| Breast Cancer |
0 |
0.37 |
| Selective Estrogen Receptor Modulators |
0 |
0.36 |
| Fractures |
0 |
0.28 |
| Menopause |
0 |
0.18 |
| California |
0 |
0.08 |
| Clinical Guidelines |
0 |
0.08 |
| Florida |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Minerals |
0 |
0.08 |
| New York |
0 |
0.08 |
| Oregon |
0 |
0.08 |
| Night Sweats |
0 |
0.07 |
| Adverse Effects |
0 |
0.04 |
| Bisphosphonate |
0 |
0.04 |
| Breast |
0 |
0.04 |
| Cancer |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Hand |
0 |
0.04 |
| Metabolism |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Skeletal |
0 |
0.04 |
| Sleep |
0 |
0.04 |
| Transdermal |
0 |
0.04 |
| Cardiovascular Risk Management |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |
| Sleep Disorders |
0 |
0.03 |